Utilization Trends and Factors Associated With ROS1 Testing Among Patients With Advanced Non–small-cell Lung Cancer in US Community Practices

William Wong, Ning Wu, Ravindra Gupta, Aaron Scott Mansfield

Research output: Contribution to journalArticle

Abstract

Testing patients with advanced non–small-cell lung cancer for relevant biomarkers, including ROS1, supports selection of appropriate targeted therapy. Among 11,409 patients in the United States with advanced non–small-cell lung cancer in 2016 to 2018, patients with certain characteristics (including being older, male, or black) were less likely to receive ROS1 testing, highlighting current gaps and opportunities to improve identification of appropriate treatment for all eligible patients.

Original languageEnglish (US)
JournalClinical lung cancer
DOIs
StateAccepted/In press - 2020

Keywords

  • Biomarker
  • ROS proto-oncogene 1 (ROS1)
  • ROS1 protein, human
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Utilization Trends and Factors Associated With ROS1 Testing Among Patients With Advanced Non–small-cell Lung Cancer in US Community Practices'. Together they form a unique fingerprint.

  • Cite this